Blog

- Uncategorized

Dual therapy activates immune defenses while damaging lung cancer DNA

A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. This combination therapy induces irreparable DNA damage in cancer cells while also stimulating the body’s immune system to combat the disease. The research is published in the journal Cell Reports Medicine.

Read More »

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.

Read More »